NasdaqGS:ZVRAPharmaceuticals
A Look At Zevra Therapeutics (ZVRA) Valuation As MIPLYFFA Patent Extension Targets 2041 Exclusivity
Zevra Therapeutics (ZVRA) is back in focus after requesting that a new patent for its approved Niemann Pick type C treatment MIPLYFFA be added to the FDA’s Orange Book, with the goal of extending exclusivity through 2041.
See our latest analysis for Zevra Therapeutics.
The Orange Book patent move has arrived alongside strong momentum, with Zevra’s share price delivering a 63.79% year to date return and a 31.22% 90 day share price return. The 3 year total shareholder return of 134.71%...